Survival of myeloma patients has greatly improved with the use of autologous stem cell
transplantation and novel agents, such as proteasome inhibitors, immunomodulatory drugs …

Curative treatment in acute myeloid leukemia (AML) depends on successful induction
therapy to achieve a complete remission (CR), and subsequent post‐remission therapy to …

Multiple myeloma is a malignant neoplasm of plasma cells that accumulate in bone marrow,
leading to bone destruction and marrow failure. This manuscript discusses the management …

Given the limited treatment options for relapsed lymphoma post–allogeneic hematopoietic
cell transplantation (post–allo-HCT) and the success of programmed death 1 (PD-1) …

Multiple myeloma (MM) is caused by the neoplastic proliferation of plasma cells. These
neoplastic plasma cells proliferate and produce monoclonal immunoglobulin in the bone …

In contrast to the upfront setting in which the role of high-dose therapy with autologous
hematopoietic cell transplantation (HCT) as consolidation of a first remission in patients with …

Lenalidomide is an effective therapeutic agent for multiple myeloma that exhibits
immunomodulatory properties including the activation of T and NK cells. The use of …

Therapeutic strategies for multiple myeloma (MM) have changed dramatically over the past
decade. Thus, the role of hematopoietic stem cell transplantation (HCT) must be considered …

Primary plasma cell leukemia (pPCL) is an aggressive plasma cell disorder with a guarded
prognosis. The diagnosis is confirmed when peripheral blood plasma cells (PCs) exceed …

With advances in allogeneic hematopoietic stem cell transplant (allo-HCT), disease relapse
has replaced transplant-related mortality as the primary cause of treatment failure for …